Centogene NV (CNTG)       2.65  +0.28 (+11.81%)

2.65  +0.28 (+11.81%)

NL0014040206 - Common Stock

News Image
7 days ago - Centogene NV

CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential...

News Image
7 days ago - Centogene NV

CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer

Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO...

News Image
21 days ago - Centogene NV

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18...

News Image
a month ago - Centogene NV

CENTOGENE’s CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework

CE-marked clinical decision support platform enables laboratories to provide best-in-class diagnostics of genetic diseases...

News Image
a month ago - Centogene NV

CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics

Newly established WGS recommendations published in the European Journal of Human Genetics Collaborative initiative leverages CENTOGENE’s differentiated...

News Image
2 months ago - Centogene NV

CENTOGENE to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential...

News Image
2 months ago - Centogene NV

CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases CENTOGENE and Takeda extend contract...

News Image
3 months ago - Centogene NV

CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results

- Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance - Focus on Pharma and Diagnostics to Position for Strong...

News Image
3 months ago - Centogene NV

CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 24, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on...

News Image
3 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Rise and shine, trader! We're starting off the day with a breakdown of the biggest pre-market stock movers for Wednesday!

News Image
3 months ago - Centogene NV

CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company...

News Image
4 months ago - Centogene NV

CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer

In November 2019, CENTOGENE first announced the signing of a data access and collaboration agreement to discover and validate novel genetic and biochemical...

News Image
4 months ago - Centogene NV

CENTOGENE Announces Voting Results of Extraordinary General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on...

News Image
5 months ago - Centogene NV

CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on...

News Image
5 months ago - Centogene NV

CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan

Enables refocusing on core business of delivering valuable, data-driven insights to patients, and pharmaceutical companies globallyEUR 15 million private...

News Image
5 months ago - Centogene NV

CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board

Nomination adds significant expertise to support pharma partnerships and an impressive track record in value creation...

News Image
5 months ago - Centogene NV

CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer

Dr. Andrin Oswald resigns as CEO due to prolonged medical leave; Kim Stratton elected as successor...

News Image
6 months ago - Centogene NV

CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development

CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC using AINPC is a...

News Image
6 months ago - Market News Video

Centogene Becomes Oversold (CNTG)

News Image
6 months ago - Centogene NV

CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Discovery

Leveraging AI to Accelerate the Path From Diagnosis to Cure...

News Image
7 months ago - Centogene NV

CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on...